SCHEMBL7978069

SCHEMBL7978069

CO/N=C(\CCc1nc(C)no1)c1ccc(Cl)c(Cl)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD4 P21917 6/20 0.43
DRD2 P14416 3/20 0.43
SLC6A4 P31645 1/20 0.41
MAPT P10636 5/20 0.36
NPSR1 Q6W5P4 2/20 0.36
ALDH1A1 P00352 2/20 0.36
HPGD P15428 2/20 0.36
GSTP1 P09211 1/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
HSD17B10 Q99714 2/20 0.35
CYP2C9 P11712 1/20 0.35
CYP2C19 P33261 1/20 0.35
TSHR P16473 2/20 0.35
LMNA P02545 2/20 0.35
HTT P42858 1/20 0.35
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
GLA P06280 1/20 0.35
MAPK1 P28482 1/20 0.35
THRB P10828 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2433682 1.00 DRD4 (0.43) DRD4DRD2SLC6A4MAPTNPSR1
SCHEMBL7974742 0.81 DRD4 (0.43) DRD4DRD2SLC6A4MAPTHPGD
SCHEMBL2433489 0.81 DRD4 (0.43) DRD4DRD2SLC6A4MAPTHPGD
SCHEMBL2438499 0.80 DRD4 (0.46) DRD4DRD2SLC6A4MAPTSMN1; SMN2
SCHEMBL2434459 0.80 DRD4 (0.46) DRD4DRD2SLC6A4MAPTSMN1; SMN2
SCHEMBL12327449 0.79 MEN1 (0.37) MAPTNPSR1ALDH1A1HPGDGSTP1
SCHEMBL2431451 0.79 MEN1 (0.42) MAPTALDH1A1HPGDGSTP1SMN1; SMN2
SCHEMBL2434132 0.78 DRD4 (0.44) DRD4DRD2SLC6A4HPGDCYP2C9
SCHEMBL2434128 0.78 DRD4 (0.44) DRD4DRD2SLC6A4HPGDCYP2C9
SCHEMBL2433288 0.73 SLC6A4 (0.60) DRD4DRD2SLC6A4HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110230428-A1 CERTAIN KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF CHDI FOUNDATION, INC. 2011-09-22 US disclosed
US-20110230428-A1 CERTAIN KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF CHDI FOUNDATION, INC. 2011-09-22 US disclosed
WO-2010011302-A1 CERTAIN KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF CHDI, INC. (US) 2010-01-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110230428-A1 CERTAIN KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF KMO, KYNU, MAOA DRD4 3036/4885DRD2 2185/4885SLC6A4 670/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.